Arcoxia - General Information
Arcoxia is a new COX-2 selective inhibitor. Current therapeutic indications are: treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. Like any other COX-2 selective inhibitor, Arcoxia selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2). This reduces the generation of prostaglandins (PGs) from arachidonic acid.
Pharmacology of Arcoxia
Arcoxia is a COX-2 selective inhibitor (approximately 106 times more selective for COX-2 inhibition over COX-1). Currently it is approved in more than 60 countries worldwide but not in the US, where the Food and Drug Administration (FDA) require additional safety and efficacy data for etoricoxib before it will issue approval.
Additional information about Arcoxia
Arcoxia Indication: For the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout.
Mechanism Of Action: Like any other COX-2 selective inhibitor Arcoxia selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2). This reduces prostaglandins (PGs) generation from arachidonic acid.
Drug Interactions: Anisindione Arcoxia increases the anticoagulant effect
Dicumarol Arcoxia increases the anticoagulant effect
Acenocoumarol Arcoxia increases the anticoagulant effect
Warfarin Arcoxia increases the anticoagulant effect
Ethinyl Estradiol Arcoxia increases levels of ethinyl estradiol
Lithium Arcoxia increases serum levels of lithium
Rifampin Rifampin reduces levels and efficacy of etoricoxib
Food Interactions: Take without regard to meals.
Generic Name: Etoricoxib
Synonyms: Not Available
Drug Category: Cyclooxygenase Inhibitors
Drug Type: Small Molecule; Approved
Other Brand Names containing Etoricoxib: Arcoxia; Nucoxia; Tauxib; Algix;
Absorption: Bioavailability is 100% following oral administration.
Toxicity (Overdose): This reduced activity is the cause of reduced gastrointestinal toxicity, as demonstrated in several large clinical trials performed with different COXIB (see below links on NEJM and The Lancet). Some clinical trials and meta-analysis showed that treatment with COXIB lead to increased incidence of cardiovascular adverse events compared to placebo
Protein Binding: 92%
Biotransformation: Hepatic, primarily via CYP3A4.
Half Life: 22 hours
Dosage Forms of Arcoxia: Not Available
Chemical IUPAC Name: 5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl)pyridine
Chemical Formula: C18H15ClN2O2S
Etoricoxib on Wikipedia: http://en.wikipedia.org/wiki/Etoricoxib
Organisms Affected: Humans and other mammals